Core Technology

Antibody drugs lead to serious side effects because they cannot distinguish disease tissue from normal tissue, which limits their application and clinical trial failure. Universal Antibody Lock is a masking structure on the binding site of an antibody that allows antibody drugs to take effect only in diseased areas, solving systemic toxicity, and making antibody treatment safe and effective. PSM101, the lead candidate for head and neck cancer and colorectal cancer treatment, will complete stable cell clone generation in 2023 and the non-human primate side effect test in 2024-Q1.